Venue: Hilton Universal City

Location: Los Angeles, California, United States

Event Date/Time: Nov 04, 2010 End Date/Time: Nov 06, 2010
Registration Date: Nov 03, 2010
Early Registration Date: Jul 31, 2010
Abstract Submission Date: Sep 10, 2010
Report as Spam


Obesity has become a global epidemic, which has reached frightening proportions. As a consequence, diabetes, hypertension and lipid disorders are progressively accelerating. We are now witnessing a reversal in the decline of cardiovascular disease that has been observed in the 20th Century.

Numerous researchers and scientists notably, Dr. Gerald Reaven – professor of Medicine, Stanford, CA – have shown that these metabolic abnormalities specifically diabetes and cardiovascular consequences are mediated by insulin resistance. The relationship between insulin resistance, obesity, dyslipidemia and hypertension was initially introduced by Dr.Reaven in 1988 as Syndrome X, now referred to as the insulin resistance, metabolic or cardio-metabolic syndrome

Multiple definitions of the Syndrome have evolved addressing the obesity epidemic, insulin resistance and their contribution to the development of CVD, diabetes, PCOS, liver disease, cancer and sleep disorders. It is also proposed complications of insulin resistance are driven by the accompanying hyperinsulinemia.

In recent years, we have become aware of the contribution of other systems to energy metabolism notably, incretins, gut hormones and bile acids. Of particular interest is the complicated relationship of the brain, the gut, fat cell and its metabolites, insulin, leptin and their respective resistance states.

The World Congress on Insulin Resistance (WCIR) has become a very important platform where the interaction of these multiple metabolic systems and their relation ship to insulin resistance are evaluated in a clinical, multi disciplinary environment. The congress has become a home to clinical and basic scientists, researchers and practicing clinicians. The highly distinguished expert faculty and the bedside to bench approach have created a state-of-the-art platform. The faculty promotes new understanding of metabolic diseases, facilitates the development of future therapeutic modalities and has been the cornerstone of the success of the congress.

This unique and exciting program has allowed the participants to personally interact with the world’s eminent leaders in insulin resistance, fat cell metabolism, the brain, incretin and gut hormones. Indeed, the program highlights tomorrow’s clinical science– today.